Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Unveiling histotype-specific biomarkers in ovarian carcinoma using proteomics

Werner, Lucas LU ; Ittner, Ella ; Swenson, Hugo ; Rönnerman, Elisabeth Werner ; Mateoiu, Claudia ; Kovács, Anikó ; Dahm-Kähler, Pernilla ; Karlsson, Per ; Thorsell, Annika and Rekabdar, Elham , et al. (2025) In Molecular Therapy Oncology 33(3).
Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, yet clinical tools for diagnosis, prognosis, and treatment remain limited, and molecular profiling of histotypes is lacking. Here, we leverage proteomic data to further stratify four main EOC histotypes, borderline (BL) and benign (B) tumors, and identify candidate prognostic and diagnostic biomarkers. Using proteomic data from 300 patient samples, we identified differentially abundant proteins (DAPs) such as SNCG, S100A1, VWA2, AGR2, CTH, and SPINK1 and biomarker panels to stratify the tissues. Enrichment of biological processes profiled histotypes and involvement of DAPs. Survival analysis identified candidate biomarkers predicting overall- and disease-specific... (More)

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, yet clinical tools for diagnosis, prognosis, and treatment remain limited, and molecular profiling of histotypes is lacking. Here, we leverage proteomic data to further stratify four main EOC histotypes, borderline (BL) and benign (B) tumors, and identify candidate prognostic and diagnostic biomarkers. Using proteomic data from 300 patient samples, we identified differentially abundant proteins (DAPs) such as SNCG, S100A1, VWA2, AGR2, CTH, and SPINK1 and biomarker panels to stratify the tissues. Enrichment of biological processes profiled histotypes and involvement of DAPs. Survival analysis identified candidate biomarkers predicting overall- and disease-specific survival with histotype-specificity. Of these, GLYR1, RPL12, GDPGP1, and POLR2M were associated with favorable outcomes, while SDF4, PPP3CC, EIF2AK2, and STX6 were linked to unfavorable outcomes. Collectively, these findings provide histotype-specific attributes for known and EOC biomarkers that may serve as clinical tools for EOC diagnosis and treatment decisions.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
benign, biomarker panels, borderline, differential abundance analysis, epithelial ovarian cancer, histotypes, MT: Regular Issue, pathway enrichment, prognostic biomarkers, survival
in
Molecular Therapy Oncology
volume
33
issue
3
article number
201019
publisher
Cell Press
external identifiers
  • scopus:105011711087
  • pmid:40778374
DOI
10.1016/j.omton.2025.201019
language
English
LU publication?
yes
id
084e8912-85e5-4aec-9b72-43b9ed3e98e8
date added to LUP
2025-11-04 14:53:28
date last changed
2025-12-02 17:16:03
@article{084e8912-85e5-4aec-9b72-43b9ed3e98e8,
  abstract     = {{<p>Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, yet clinical tools for diagnosis, prognosis, and treatment remain limited, and molecular profiling of histotypes is lacking. Here, we leverage proteomic data to further stratify four main EOC histotypes, borderline (BL) and benign (B) tumors, and identify candidate prognostic and diagnostic biomarkers. Using proteomic data from 300 patient samples, we identified differentially abundant proteins (DAPs) such as SNCG, S100A1, VWA2, AGR2, CTH, and SPINK1 and biomarker panels to stratify the tissues. Enrichment of biological processes profiled histotypes and involvement of DAPs. Survival analysis identified candidate biomarkers predicting overall- and disease-specific survival with histotype-specificity. Of these, GLYR1, RPL12, GDPGP1, and POLR2M were associated with favorable outcomes, while SDF4, PPP3CC, EIF2AK2, and STX6 were linked to unfavorable outcomes. Collectively, these findings provide histotype-specific attributes for known and EOC biomarkers that may serve as clinical tools for EOC diagnosis and treatment decisions.</p>}},
  author       = {{Werner, Lucas and Ittner, Ella and Swenson, Hugo and Rönnerman, Elisabeth Werner and Mateoiu, Claudia and Kovács, Anikó and Dahm-Kähler, Pernilla and Karlsson, Per and Thorsell, Annika and Rekabdar, Elham and Esmaeili, Parisa and Levander, Fredrik and Forssell-Aronsson, Eva and Tullberg, Axel Stenmark and Saed, Ghassan and Parris, Toshima Z. and Helou, Khalil}},
  keywords     = {{benign; biomarker panels; borderline; differential abundance analysis; epithelial ovarian cancer; histotypes; MT: Regular Issue; pathway enrichment; prognostic biomarkers; survival}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{Cell Press}},
  series       = {{Molecular Therapy Oncology}},
  title        = {{Unveiling histotype-specific biomarkers in ovarian carcinoma using proteomics}},
  url          = {{http://dx.doi.org/10.1016/j.omton.2025.201019}},
  doi          = {{10.1016/j.omton.2025.201019}},
  volume       = {{33}},
  year         = {{2025}},
}